Skip to main content

Zalcitabine Disease Interactions

There are 3 disease interactions with zalcitabine.

Major

DdC (applies to zalcitabine) cardiomyopathy

Major Potential Hazard, Low plausibility. Applicable conditions: Congestive Heart Failure

The use of zalcitabine (ddC) has been associated rarely with cardiomyopathy and congestive heart failure in patients with AIDS. Therapy with ddC should be administered cautiously in patients with preexisting cardiomyopathy or a history of congestive heart failure.

References

  1. (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories
Major

NRTIs (applies to zalcitabine) bone marrow suppression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC) and stavudine (d4T), may infrequently cause bone marrow suppression at recommended dosages. Anemia, leukopenia, thrombocytopenia and neutropenia have been reported. Therapy with these agents should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias. Routine blood counts are recommended.

References

  1. (2002) "Product Information. Videx (didanosine)." Bristol-Myers Squibb
  2. (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories
  3. (2001) "Product Information. Zerit (stavudine)." Bristol-Myers Squibb
Major

NRTIs (applies to zalcitabine) peripheral neuropathy

Major Potential Hazard, High plausibility.

The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), and stavudine (d4T), may commonly cause dose-related peripheral neuropathy, particularly in patients with advanced HIV disease. Usually, the neuropathy resolves slowly following prompt discontinuation of therapy, but it can be irreversible. These agents should be administered cautiously to patients with a history of neuropathy and avoided in patients with existing polyneuropathy. Therapy may be reinstituted following resolution of symptoms in patients who have previously experienced neuropathy with these drugs, but reduced dosages are recommended.

References

  1. LeLacheur SF, Simon GL (1991) "Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine." J Acquir Immune Defic Syndr, 4, p. 538-9
  2. Broder S, Yarchoan R (1990) "Dideoxycytidine: current clinical experience and future prospects." Am J Med, 88, s31-3
  3. Dubinsky RM, Yarchoan R, Dalakas M, Broder S (1989) "Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC)." Muscle Nerve, 12, p. 856-60
  4. Dubinsky RM, Dalakas M, Yarchoan R, Broder S (1988) "Follow-up of neuropathy from 2'3'-dideoxycytidine." Lancet, 1, p. 832
  5. Whittington R, Brogden RN (1992) "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs, 44, p. 656-83
  6. Matthews SJ, Cersosimo RJ, Spivack ML (1991) "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy, 11, p. 419-49
  7. (2002) "Product Information. Videx (didanosine)." Bristol-Myers Squibb
  8. (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories
  9. Martinez OP, French MA (1993) "Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy." AIDS, 7, p. 901-2
  10. (2001) "Product Information. Zerit (stavudine)." Bristol-Myers Squibb
  11. Fichtenbaum CJ, Clifford DB, Powderly WG (1995) "Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection." J Acquir Immune Defic Syndr Hum Retrovirol, 10, p. 169-74
  12. Moore RD, Fortgang I, Keruly J, Chaisson RE (1996) "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med, 101, p. 34-40
View all 12 references

Zalcitabine drug interactions

There are 144 drug interactions with zalcitabine.

Zalcitabine alcohol/food interactions

There is 1 alcohol/food interaction with zalcitabine.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer